medicalnewstoday.com
May 22, 2008
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that investigators presented clinical data on two Phase 3 products at the American Urological Association's annual meeting. The abstract (Steady-State Pharmacokinetics of an Investigational...
[read full story]